ILRI deploys the Nobel Prize-winning technology, CRISPR-Cas9, to accelerate African swine fever vaccine development
Scientists at the International Livestock Research Institute (ILRI) have been working to develop a vaccine for African swine fever, a lethal and contagious haemorrhagic viral disease in domestic pigs caused by the African swine fever virus (ASFV). Currently there are no vaccines on the market, but several are under development. Scientists at ILRI are applying the cutting-edge Nobel Prize-winning genome editing technology known as CRISPR technology to fast-track rational development of live-attenuated ASFV vaccine candidates. ILRI scientists have generated 10 ASFV vaccine candidates due to be tested for their safety and efficacy beginning the first quarter of 2021.